[HTML][HTML] Advances on EGFR mutation for lung cancer
G Metro, L Crinò - Translational lung cancer research, 2012 - ncbi.nlm.nih.gov
Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating
mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) …
mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) …
[HTML][HTML] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with …
S Sugawara, S Oizumi, K Minato, T Harada, A Inoue… - Annals of oncology, 2015 - Elsevier
ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …